| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 700 | 620 | 970 | 5,330 | 24,450 |
| Sales Growth | +12.90% | -36.08% | -81.80% | -78.20% | +110.96% |
| Net Income | -84,830 | -67,610 | -59,730 | -59,430 | -45,200 |
| Net Income Growth | -25.47% | -13.19% | -0.50% | -31.48% | -9.18% |
Eyepoint Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
EYEPOINT INC is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. EYEPOINT INC, formerly known as EyePoint Pharmaceuticals Inc., is based in WATERTOWN, Mass.
Fiscal Year End Date: 12/31